Kangstem Biotech Applies for Phase 3 Clinical Trial of PureSystem-AD Injection for Chronic Atopic Dermatitis

[Asia Economy Reporter Minji Lee] Kangstem Biotech announced on the 29th that it has applied to the Ministry of Food and Drug Safety (MFDS) for a Phase 3 clinical trial to evaluate the efficacy and safety of PureSystem-AD injection in patients with moderate to severe chronic atopic dermatitis.